Endothelial dysfunction and lung capillary injury in cardiovascular diseases

Progress in Cardiovascular Diseases

Volumn 57, Issue 5, 2015, Pages 454-462

  Guazzi, Marco ^a   Phillips, Shane A ^b   Arena, Ross ^b   Lavie, Carl J ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alveolar capillary unit; Endothelial dysfunction; Lung capillaries

Indexed keywords

CARBON MONOXIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PHOSPHODIESTERASE V; SILDENAFIL;

ARTICLE; CARDIOVASCULAR DISEASE; CELL HYPOXIA; CELL SURFACE; CORRELATIONAL STUDY; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG ALVEOLUS CELL; LUNG CAPILLARY; LUNG CAPILLARY PRESSURE; LUNG CLEARANCE; LUNG DIFFUSION; LUNG FLUID; LUNG GAS EXCHANGE; LUNG INJURY; MICROANGIOPATHY; MICROCIRCULATION; NONHUMAN; PATHOPHYSIOLOGY; ANIMAL; CAPILLARY; CAPILLARY PERMEABILITY; COMPLICATION; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES; PATHOLOGY; PROGNOSIS; RISK FACTOR; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; VASCULARIZATION;

ANIMALS; BLOOD-AIR BARRIER; CAPILLARIES; CAPILLARY PERMEABILITY; ENDOTHELIUM, VASCULAR; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; LUNG; LUNG DISEASES; PROGNOSIS; PULMONARY GAS EXCHANGE; RISK FACTORS; VASCULAR REMODELING;

EID: 84924767073     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2014.11.003     Document Type: Article

References (67)

1. Meyer T., Shih J., Aurigemma G. Heart failure with preserved ejection fraction (diastolic dysfunction). Ann Intern Med 2013, 158. [ITC5-1-ITC5-15; quiz ITC15-16].
2. Gandhi S.K., Powers J.C., Nomeir A.M., et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med 2001, 344:17-22.
3. Guazzi M., Borlaug B.A. Pulmonary hypertension due to left heart disease. Circulation 2012, 126:975-990.
4. Guazzi M., Bandera F., Pelissero G., et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 2013, 305:H1373-H1381.
5. Solomonica A., Burger A.J., Aronson D. Hemodynamic determinants of dyspnea improvement in acute decompensated heart failure. Circ Heart Fail 2013, 6:53-60.
6. Dupuis J., Guazzi M. The clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart disease. Can J Cardiol 2014, 10.1016/j.cjca.2014.10.012.
7. Park J.E., Lyon A.R., Shao D., et al. Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models. Thorax 2014, 12:1120-1127.
8. West J.B., Mathieu-Costello O. Vulnerability of pulmonary capillaries in heart disease. Circulation 1995, 92:622-631.
9. Guazzi M., Arena R. Pulmonary hypertension with left-sided heart disease. Nat Rev Cardiol 2010, 7:648-659.
10. Tsukimoto K., Mathieu-Costello O., Prediletto R., Elliott A.R., West J.B. Ultrastructural appearances of pulmonary capillaries at high transmural pressures. J Appl Physiol 1991, 71:573-582.
11. Conforti E., Fenoglio C., Bernocchi G., Bruschi O., Miserocchi G.A. Morpho-functional analysis of lung tissue in mild interstitial edema. Am J Physiol Lung Cell Mol Physiol 2002, 282:L766-L774.
12. Palestini P., Calvi C., Conforti E., Botto L., Fenoglio C., Miserocchi G. Composition, biophysical properties, and morphometry of plasma membranes in pulmonary interstitial edema. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1382-L1390.
13. De Pasquale C.G., Arnolda L.F., Doyle I.R., Aylward P.E., Chew D.P., Bersten A.D. Plasma surfactant protein-b: a novel biomarker in chronic heart failure. Circulation 2004, 110:1091-1096.
14. Ravi Y., Selvendiran K., Naidu S.K., et al. Pulmonary hypertension secondary to left-heart failure involves peroxynitrite-induced downregulation of PTEN in the lung. Hypertension 2013, 61:593-601.
15. Townsley M.I., Fu Z., Mathieu-Costello O., West J.B. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res 1995, 77:317-325.
16. Kingsbury M.P., Huang W., Donnelly J.L., et al. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 2003, 98:295-303.
17. Chen D.D., Dong Y.G., Yuan H., Chen A.F. Endothelin 1 activation of endothelin a receptor/nadph oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension. Hypertension 2012, 59:1037-1043.
18. Kay J.M., Edwards F.R. Ultrastructure of the alveolar-capillary wall in mitral stenosis. J Pathol 1973, 111:239-245.
19. Lee Y.S. Electron microscopic studies on the alveolar-capillary barrier in the patients of chronic pulmonary edema. Jpn Circ J 1979, 43:945-954.
20. Kapanci Y., Burgan S., Pietra G.G., Conne B., Gabbiani G. Modulation of actin isoform expression in alveolar myofibroblasts (contractile interstitial cells) during pulmonary hypertension. Am J Pathol 1990, 136:881-889.
21. Kim K.K., Kugler M.C., Wolters P.J., et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A 2006, 103:13180-13185.
22. Razani B., Engelman J.A., Wang X.B., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138.
23. Jasmin J.F., Mercier I., Hnasko R., et al. Lung remodeling and pulmonary hypertension after myocardial infarction: pathogenic role of reduced caveolin expression. Cardiovasc Res 2004, 63:747-755.
24. Drake R.E., Doursout M.F. Pulmonary edema and elevated left atrial pressure: four hours and beyond. News Physiol Sci 2002, 17:223-226.
25. Berg J.T., Breen E.C., Fu Z., Mathieu-Costello O., West J.B. Alveolar hypoxia increases gene expression of extracellular matrix proteins and platelet-derived growth factor-b in lung parenchyma. Am J Respir Crit Care Med 1998, 158:1920-1928.
26. Guazzi M. Alveolar gas diffusion abnormalities in heart failure. J Card Fail 2008, 14:695-702.
27. Guazzi M., Reina G., Tumminello G., Guazzi M.D. Alveolar-capillary membrane conductance is the best pulmonary function correlate of exercise ventilation efficiency in heart failure patients. Eur J Heart Fail 2005, 7:1017-1022.
28. Moraes D.L., Colucci W.S., Givertz M.M. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
29. Cooper C.J., Jevnikar F.W., Walsh T., Dickinson J., Mouhaffel A., Selwyn A.P. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 1998, 82:609-614.
30. Ooi H., Colucci W.S., Givertz M.M. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation 2002, 106:1618-1621.
31. Kerem A., Yin J., Kaestle S.M., et al. Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization. Circ Res 2010, 106:1103-1116.
32. Stamler J.S., Loh E., Roddy M.A., Currie K.E., Creager M.A. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994, 89:2035-2040.
33. Hsia C.C. Recruitment of lung diffusing capacity: update of concept and application. Chest 2002, 122:1774-1783.
34. Guazzi M., Arena R., Vicenzi M., Guazzi M.D. Regulation of alveolar gas conductance by NO in man, as based on studies with NO donors and inhibitors of NO production. Acta Physiol (Oxf) 2009, 196:267-277.
35. Porter T.R., Taylor D.O., Cycan A., et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 1993, 22:1418-1424.
36. Bland R.D. Lung epithelial ion transport and fluid movement during the perinatal period. Am J Physiol 1990, 259:L30-L37.
37. Matalon S., O'Brodovich H. Sodium channels in alveolar epithelial cells: molecular characterization, biophysical properties, and physiological significance. Annu Rev Physiol 1999, 61:627-661.
38. Murray F., MacLean M.R., Pyne N.J. Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension. Br J Pharmacol 2002, 137:1187-1194.
39. Hughes JMB M.J., Nadel J.A. The lungs in heart disease. Textbook of respiratory medicine 1994, 2200-2222. WB Saunders Co., London. 2nd ed.
40. Azzam Z.S., Dumasius V., Saldias F.J., Adir Y., Sznajder J.I., Factor P. Na, K-ATPase overexpression improves alveolar fluid clearance in a rat model of elevated left atrial pressure. Circulation 2002, 105:497-501.
41. Suzuki S., Noda M., Sugita M., Ono S., Koike K., Fujimura S. Impairment of transalveolar fluid transport and lung Na+-K+-ATPase function by hypoxia in rats. J Appl Physiol 1999, 87:962-968.
42. Farrero M., Blanco I., Batlle M., et al. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 2014, 7:791-798.
43. Magini A., Apostolo A., Salvioni E., Italiano G., Veglia F., Agostoni P. Alveolar-capillary membrane diffusion measurement by nitric oxide inhalation in heart failure. Eur J Prev Cardiol 2013, [in press].
44. Roughton F.J., Forster R.E. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol 1957, 11:290-302.
45. Puri S., Baker B.L., Dutka D.P., Oakley C.M., Hughes J.M., Cleland J.G. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. Circulation 1995, 91:2769-2774.
46. Guazzi M., Marenzi G., Alimento M., Contini M., Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997, 95:1930-1936.
47. Assayag P., Benamer H., Aubry P., et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol 1998, 82:459-464.
48. Abraham M.R., Olson L.J., Joyner M.J., Turner S.T., Beck K.C., Johnson B.D. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation 2002, 106:1794-1799.
49. Guazzi M., Brambilla R., Pontone G., Agostoni P., Guazzi M.D. Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure. Am J Cardiol 2002, 89:191-197.
50. Puri S., Dutka D.P., Baker B.L., Hughes J.M., Cleland J.G. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation 1999, 99:1190-1196.
51. Guazzi M., Agostoni P., Bussotti M., Guazzi M.D. Impeded alveolar-capillary gas transfer with saline infusion in heart failure. Hypertension 1999, 34:1202-1207.
52. Smith A.A., Cowburn P.J., Parker M.E., et al. Impaired pulmonary diffusion during exercise in patients with chronic heart failure. Circulation 1999, 100:1406-1410.
53. Guazzi M., Reina G., Tumminello G., Guazzi M.D. Exercise ventilation inefficiency and cardiovascular mortality in heart failure: the critical independent prognostic value of the arterial CO2 partial pressure. Eur Heart J 2005, 26:472-480.
54. Agostoni P., Cattadori G., Bianchi M., Wasserman K. Exercise-induced pulmonary edema in heart failure. Circulation 2003, 108:2666-2671.
55. Dupuis J., Guazzi M. The clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases. Can J Cardiol 2015, [in press].
56. Mettauer B., Lampert E., Charloux A., et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol 1999, 83:62-67.
57. Guazzi M., Pontone G., Brambilla R., Agostoni P., Reina G. Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. Eur Heart J 2002, 23:467-476.
58. Guazzi M., Agostoni P. Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Clin Sci (Lond) 1999, 96:17-22.
59. Guazzi M., Agostoni P., Guazzi M.D. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. J Am Coll Cardiol 2001, 37:398-406.
60. Guazzi M., Agostoni P., Matturri M., Pontone G., Guazzi M.D. Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J 1999, 138:460-467.
61. Singh S.N., Fisher S.G., Deedwania P.C., Rohatgi P., Singh B.N., Fletcher R.D. Pulmonary effect of amiodarone in patients with heart failure. The Congestive Heart Failure-Survival Trial of Antiarrhythmic Therapy (CHF-STAT) Investigators (Veterans Affairs Cooperative Study No. 320). J Am Coll Cardiol 1997, 30:514-517.
62. Yin J., Kukucka M., Hoffmann J., et al. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail 2011, 4:198-206.
63. Melenovsky V., Al-Hiti H., Kazdova L., et al. Transpulmonary b-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil. J Am Coll Cardiol 2009, 54:595-600.
64. Guazzi M., Vicenzi M., Arena R., Guazzi M.D. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124:164-174.
65. Bonderman D., Ghio S., Felix S.B., et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013, 128:502-511. Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial Study G.
66. Bonderman D., Pretsch I., Steringer-Mascherbauer R., et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 2014, 146:1274-1285.
67. Guazzi M., Reina G., Tumminello G., Guazzi M.D. Improvement of alveolar-capillary membrane diffusing capacity with exercise training in chronic heart failure 2004, 97:1866-1873.